Advertisement
U.S. markets close in 3 hours 50 minutes
  • S&P 500

    5,252.38
    +3.89 (+0.07%)
     
  • Dow 30

    39,778.43
    +18.35 (+0.05%)
     
  • Nasdaq

    16,388.62
    -10.90 (-0.07%)
     
  • Russell 2000

    2,135.01
    +20.66 (+0.98%)
     
  • Crude Oil

    82.57
    +1.22 (+1.50%)
     
  • Gold

    2,235.00
    +22.30 (+1.01%)
     
  • Silver

    24.89
    +0.14 (+0.56%)
     
  • EUR/USD

    1.0797
    -0.0033 (-0.30%)
     
  • 10-Yr Bond

    4.1850
    -0.0110 (-0.26%)
     
  • GBP/USD

    1.2629
    -0.0009 (-0.07%)
     
  • USD/JPY

    151.3520
    +0.1060 (+0.07%)
     
  • Bitcoin USD

    70,868.82
    +1,826.44 (+2.65%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,964.97
    +32.99 (+0.42%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Valneva Concludes Recruitment for COVID-19 Vaccine Candidate Trial

  • Privately-held Valneva SE has completed recruitment for the pivotal Phase 3 trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.

  • VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, combined with two adjuvants, alum and Dynavax Technologies Corporation’s (NASDAQ: DVAX) CpG 1018.

  • Over 4,000 volunteers in the U.K. have been randomized in the Phase 3 trial “Cov-Compare,” which compares Valneva’s SARS-CoV-2 vaccine candidate, VLA2001, against AstraZeneca Plc’s (NASDAQ: AZN) conditionally approved vaccine, Vaxzevria1.

  • Topline data are expected by September 2021, and submission to the U.K.’s Medicines and Healthcare products Regulatory Agency for regulatory approval will follow.

  • Price Action: DVAX shares are up 2.02% at $8.59 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement